| Theme | Calcitonin -- update | |
|---|---|---|
| Title | The role of calcitonin in the treatment of renal osteodystrophy | |
| Publish Date | 2001/10 | |
| Author | Naohiko Katoh | Division of Nephrology and Hypertension, The Jikei University School of Medicine |
| Author | Takashi Shigematsu | Division of Nephrology and Hypertension, The Jikei University School of Medicine |
| [ Summary ] | Calcitonin is powerful inhibitors on osteoclast. Kanis suggested that a possible factor in pathogenesis of renal bone disease is a failure to secrete calcitonin, but Malluche sugested that endogenous calcitonin is not protective against hyperparathyroidism. Calcitonin may be usefully employed in renal osteodystrophy in some occasions. Good clinical indications of calcitonin are secondary hyperparathy roidism, hypercalcemia, hyperphosphatemia, metastatic calcification, and bone pain. There are several clinical investigations of calcitonin in hemodialysis patients. |
|